Dmitry Garmaev
Pain Medicine · Farmington, NMNPI 1720321532
Payments from drug & device makers
What this record shows
13 manufacturers reported payments, led by Abbott at 39.4% of the total. Reporting peaked in 2019 at $3,245 and has fallen 71.1% since, to $938 in 2025.
Across 132 payments — averaging $57.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$2K
- Relievant Medsystems, Inc.$1K
- Si-bone, Inc.$643
- Boston Scientific$500
- Nevro Corp.$40
- plus $173 from 7 others
What the payments were for
- Travel & lodging$4,17655%
- Food & beverage$3,44845%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 77 | $3,006 |
| Medtronic(2 entities) | 18 | $1,931 |
| Relievant Medsystems, Inc. | 9 | $1,332 |
| Si-bone, Inc. | 8 | $643 |
| Boston Scientific | 9 | $500 |
| Nevro Corp. | 2 | $40 |
| AbbVie(2 entities) | 2 | $37 |
| Avanos Medical | 1 | $35 |
| Pacira Pharmaceuticals Incorporated | 2 | $33 |
| Tersera Therapeutics LLC | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Pacira Therapeutics, Inc. | 1 | $18 |
| Nalu Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$2,129
- INTELLIS$1,054
- Proclaim Family of SCS IPGs$909
- IFUSE IMPLANT SYSTEM$435
- ADAPTIVESTIM$336
- SUPERION$182
- Axium INS DRG IPG$155
- ETERNA$112
- LIORESAL$109
How this compares
$7,625 in reported general payments places this provider in the 85th percentile of 36 pain medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 41 | $388 |
| Tizanidine Hcl | 11 | $121 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Farmington
- Jonathan JonesFarmington$6K
- John WatkinsAlbuquerque$22K
- Craig RumbaughAlbuquerque$11K
- Eugene KoshkinAlbuquerque$10K
- Llewelyn WilliamsLas Cruces$8K
- Matthew BergstenAlbuquerque$7K
- Lauren HarrisAlbuquerque$6K
- Melissa MerhegeAlbuquerque$5K
- Jeremy ChastainAlbuquerque$5K
- Joshu RaitenAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.